ImmunityBio (IBRX) Equity Ratio (2016 - 2025)
Historic Equity Ratio for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to 1.01.
- ImmunityBio's Equity Ratio rose 5050.6% to 1.01 in Q3 2025 from the same period last year, while for Sep 2025 it was 1.01, marking a year-over-year increase of 5050.6%. This contributed to the annual value of 1.28 for FY2024, which is 976.51% down from last year.
- According to the latest figures from Q3 2025, ImmunityBio's Equity Ratio is 1.01, which was up 5050.6% from 1.42 recorded in Q2 2025.
- ImmunityBio's Equity Ratio's 5-year high stood at 0.52 during Q4 2021, with a 5-year trough of 2.22 in Q2 2023.
- Its 5-year average for Equity Ratio is 1.29, with a median of 1.24 in 2022.
- Per our database at Business Quant, ImmunityBio's Equity Ratio tumbled by 97838.83% in 2021 and then soared by 5050.6% in 2025.
- Quarter analysis of 5 years shows ImmunityBio's Equity Ratio stood at 0.52 in 2021, then tumbled by 138.65% to 1.24 in 2022, then grew by 6.26% to 1.16 in 2023, then decreased by 9.77% to 1.28 in 2024, then rose by 20.9% to 1.01 in 2025.
- Its Equity Ratio stands at 1.01 for Q3 2025, versus 1.42 for Q2 2025 and 1.95 for Q1 2025.